Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;25(3):455-62.
doi: 10.3233/JAD-2011-110011.

Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2

Affiliations

Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2

Caroline R Elliott-Hunt et al. J Alzheimers Dis. 2011.

Abstract

Expression of the neuropeptide galanin is known to be upregulated in the brain of patients with Alzheimer's disease (AD). We and others have shown that galanin plays a neuroprotective role in a number of excitotoxic injury paradigms, mediated by activation of the second galanin receptor subtype (GAL2). In the present study, we investigated whether galanin/GAL2 plays a similar protective role against amyloid-β(Aβ) toxicity. Here we report that galanin or the GAL2/3-specific peptide agonist Gal2-11, both equally protect primary dispersed mouse wildtype (WT) neonatal hippocampal neurons from 250 nM Aβ1-42 toxicity in a dose dependent manner. The amount of Aβ1-42 induced cell death was significantly greater in mice with loss-of-function mutations in galanin (Gal-KO) or GAL2 (GAL2-MUT) compared to strain-matched WT controls. Conversely, cell death was significantly reduced in galanin over-expressing (Gal-OE) transgenic mice compared to strain-matched WT controls. Exogenous galanin or Gal2-11 rescued the deficits in the Gal-KO but not the GAL2-MUT cultures, confirming that the protective effects of endogenous or exogenous galanin are mediated by activation of GAL2. Despite the high levels of endogenous galanin in the Gal-OE cultures, the addition of exogenous 100 nM or 50 nM galanin or 100 nM Gal2-11 further significantly reduced cell death, implying that GAL2-mediated neuroprotection is not at maximum in the Gal-OE mice. These data further support the hypothesis that galanin over-expression in AD is a neuroprotective response and imply that the development of a drug-like GAL2 agonist might reduce the progression of symptoms in patients with AD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage cell death in (A) Gal-KO and (B) GAL2-MUT both compared to strain matched WT hippocampal cultures, treated with 250 nM fA_1-42 in the presence of varying concentrations of galanin or Gal2-11. In both loss-of-function mutations there is a significant increase in fA_1–42 and glutamate-induced cell death compared to strain-matched WT cultures. Addition of galanin or Gal2-11 significantly rescues the deficits in the Gal-KO but not the GAL2-MUT cultures. **p < 0.01 treatment versus control. §p < 0.05 Gal-KO or GAL2-MUT versus WT. §§p < 0.01 GAL2-MUT versus WT. +p < 0.05 treatment different to fA_1–42 or glutamate alone. ++p < 0.01 treatment different to fA_1–42 or glutamate alone.
Fig. 2
Fig. 2
Percentage cell death in Gal-OE and strain matched WT hippocampal cultures treated with 250 nM fA_1–42 in the presence of varying concentrations of galanin or Gal2-11. In the Gal-OE mice there is a significant decrease in fA_1–42 and glutamate-induced cell death compared to strain-matched WT cultures. Addition of 100 nM and 50 nM galanin or 100 nM Gal2-11 further and significantly rescues the cell death. **p < 0.01 treatment versus control. §§p < 0.01 Gal-OE versus WT. +p < 0.05 treatment different to fA_1–42 or glutamate alone. ++p < 0.01 treatment different to fA_1–42 or glutamate alone.

Similar articles

Cited by

References

    1. Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993;75:1039–1042. - PubMed
    1. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890. - PubMed
    1. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879–10883. - PMC - PubMed
    1. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer’s disease. J Biol Chem. 1996;271:18295–18298. - PubMed
    1. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–791. - PubMed

Publication types

MeSH terms

LinkOut - more resources